Zymeworks (ZYME) Interest Expenses (2021 - 2026)
Zymeworks (ZYME) posted Interest Expenses of $19.4 million for Q1 2026, up 1712.43% sequentially from $1.1 million in Q4 2025, and up 1750.48% YoY from $1.0 million in Q1 2025.
Zymeworks (ZYME) Interest Expenses (2021 - 2026) Analysis & Trends
Zymeworks has reported Interest Expenses for 6 years, with the latest figure at $19.4 million in Q1 2026.
- Quarterly Interest Expenses rose 1750.48% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 402.54% YoY) and the FY2025 annual result came in at $274.5 million, up 10.13% from the prior year.
- Interest Expenses grew to $19.4 million in Q1 2026 per ZYME's latest filing, from $1.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $35.3 million in Q3 2022 and troughed at $881000.0 in Q2 2024.
- A 5-year average of $12.1 million and a median of $1.3 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 97.23% in 2024, then jumped 2321.57% in 2025.
- Over 5 years, Interest Expenses stood at $1.1 million in 2022, then climbed by 22.67% to $1.4 million in 2023, then declined by 29.27% to $957000.0 in 2024, then grew by 11.81% to $1.1 million in 2025, then surged by 1712.43% to $19.4 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $19.4 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | 86.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.34 Mn |
| Jun 30, 2026 | 86.34 Mn |
| Mar 31, 2026 | 19.39 Mn |
| Mar 31, 2026 | 19.39 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 21.33 Mn |
| Jun 30, 2025 | 21.33 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 957,000.00 |
| Dec 31, 2024 | 957,000.00 |
| Sep 30, 2024 | 973,000.00 |
| Sep 30, 2024 | 973,000.00 |
| Jun 30, 2024 | 881,000.00 |
| Jun 30, 2024 | 881,000.00 |
| Mar 31, 2024 | 1.34 Mn |
| Mar 31, 2024 | 1.34 Mn |